Literature DB >> 11892835

Dominant negative c-jun gene transfer inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in rats.

H Yasumoto1, S Kim, Y Zhan, H Miyazaki, M Hoshiga, Y Kaneda, R Morishita, H Iwao.   

Abstract

We previously reported that activator protein-1 (AP-1), containing c-Jun, is rapidly activated in balloon-injured artery. Therefore, we examined the role of c-Jun in vascular smooth muscle cell (SMC) proliferation, by using in vitro and in vivo gene transfer techniques. (1) Serum (2%) stimulation significantly increased AP-1 DNA binding activity in aortic SMCs, followed by the increase in both 3H-thymidine incorporation and cell number. Aortic SMCs were infected with recombinant adenovirus containing TAM67, a dominant negative c-Jun lacking transactivation domain of wild c-Jun (Ad-DN-c-Jun), to specifically inhibit AP-1. Ad-DN-c-Jun significantly inhibited serum-induced SMC proliferation, by inhibiting the entrance of SMC into S phase. (2) The effect of DN-c-Jun was examined on balloon injury-induced intimal hyperplasia in rats. Before balloon injury, DN-c-Jun was transfected into rat carotid artery using the hemagglutinating virus of Japan-liposome method. In vivo transfection of DN-c-Jun significantly inhibited vascular SMC proliferation in the intima and the media and subsequently prevented intimal thickening at 14 days after balloon injury. We obtained the first evidence that DN-c-Jun gene transfer prevented vascular SMC proliferation in vitro and in vivo, and c-Jun was involved in balloon injury-induced intimal hyperplasia. Thus, AP-1 seems to be the new therapeutic target for treatment of vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11892835     DOI: 10.1038/sj.gt.3301590

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  17 in total

Review 1.  Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury.

Authors:  Neeta Adhikari; Nathan Charles; Ute Lehmann; Jennifer L Hall
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

Review 2.  AP-1 and colorectal cancer.

Authors:  Reiko Ashida; Kazunari Tominaga; Eiji Sasaki; Toshio Watanabe; Yasuhiro Fujiwara; Nobuhide Oshitani; Kazuhide Higuchi; Shokei Mitsuyama; Hiroshi Iwao; Tetsuo Arakawa
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

3.  Interleukin-17 augments tumor necrosis factor-alpha-induced granulocyte and granulocyte/macrophage colony-stimulating factor release from human colonic myofibroblasts.

Authors:  Akira Andoh; Hirofumi Yasui; Osamu Inatomi; Zhuobin Zhang; Yasuyuki Deguchi; Kazunori Hata; Yoshio Araki; Tomoyuki Tsujikawa; Katsuyuki Kitoh; Shokei Kim-Mitsuyama; Atsushi Takayanagi; Nobuyoshi Shimizu; Yoshihide Fujiyama
Journal:  J Gastroenterol       Date:  2005-08       Impact factor: 7.527

4.  Identify potential drugs for cardiovascular diseases caused by stress-induced genes in vascular smooth muscle cells.

Authors:  Chien-Hung Huang; Jin-Shuei Ciou; Shun-Tsung Chen; Victor C Kok; Yi Chung; Jeffrey J P Tsai; Nilubon Kurubanjerdjit; Chi-Ying F Huang; Ka-Lok Ng
Journal:  PeerJ       Date:  2016-09-28       Impact factor: 2.984

5.  A Novel ASK Inhibitor AGI-1067 Inhibits TLR-4-Mediated Activation of ASK1 by Preventing Dissociation of Thioredoxin from ASK1.

Authors:  Shuhui Zheng; Lingli Long; Yonghao Li; Yuxia Xu; Zhang Jiqin; Weidong Ji; Wang Min
Journal:  Cardiovasc Pharm Open Access       Date:  2015-02-26

6.  p21-activated kinase 1 participates in vascular remodeling in vitro and in vivo.

Authors:  Akinari Hinoki; Keita Kimura; Sadaharu Higuchi; Kunie Eguchi; Akira Takaguri; Kazuhiro Ishimaru; Gerald D Frank; William T Gerthoffer; Laura J Sommerville; Michael V Autieri; Satoru Eguchi
Journal:  Hypertension       Date:  2009-11-09       Impact factor: 10.190

7.  The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease.

Authors:  T Sugihara; A Kobori; H Imaeda; T Tsujikawa; K Amagase; K Takeuchi; Y Fujiyama; A Andoh
Journal:  Clin Exp Immunol       Date:  2010-01-19       Impact factor: 4.330

8.  Regulation of MafA expression in pancreatic beta-cells in db/db mice with diabetes.

Authors:  Taka-aki Matsuoka; Hideaki Kaneto; Takeshi Miyatsuka; Tsunehiko Yamamoto; Kaoru Yamamoto; Ken Kato; Iichiro Shimomura; Roland Stein; Munehide Matsuhisa
Journal:  Diabetes       Date:  2010-04-27       Impact factor: 9.461

9.  Interleukin-32 expression in the pancreas.

Authors:  Atsushi Nishida; Akira Andoh; Osamu Inatomi; Yoshihide Fujiyama
Journal:  J Biol Chem       Date:  2009-04-21       Impact factor: 5.157

10.  Epithelial expression of interleukin-37b in inflammatory bowel disease.

Authors:  H Imaeda; K Takahashi; T Fujimoto; E Kasumi; H Ban; S Bamba; H Sonoda; T Shimizu; Y Fujiyama; A Andoh
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.